In the latest episode of consulting company Cell One Partners’ video series—Cell One Insights—on cell and gene therapy, Stephen Chang, PhD—a human geneticist and partner at Cell One Partners—shares insights from his 40...
BiomX (NYSE: PHGE) has announced the initiation of patient dosing in its Phase 2b trial evaluating BX004 for the treatment of cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas...
Firefly Neuroscience (NASDAQ: AIFF) has announced its continued collaboration with Prof. Christian Schaaf, MD, Director of the Institute of Human Genetics at Heidelberg University Hospital and Chairman of Human Genetics...
MiNK Therapeutics (NASDAQ: INKT) has highlighted a publication in the peer-reviewed journal Oncogene describing a complete and durable remission in a patient with metastatic, treatment refractory testicular cancer...
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) has announced that China’s National Medical Products Administration (NMPA) has approved its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) for the...
Closely held PharmaJet has announced the signing of a Memorandum of Understanding (MOU) with the Egyptian Unified Procurement Authority (UPA) and closely held EVA Pharma. The agreement aims to explore the integration of...
Cogent Biosciences (NASDAQ: COGT) has announced positive topline results from the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis (NonAdvSM), achieving statistical significance across...
MedMira (TSXV: MIR) has announced the launch of a clinical trial to evaluate its Multiplo TP/HIV rapid test for use as a self-test in Canada. Multiplo is a dual HIV and syphilis rapid self-test that delivers immediate...
Cyclacel Pharmaceuticals (NASDAQ: CYCC; NASDAQ: CYCCP) has announced the publication of independent research in the peer-reviewed medical journal Gut demonstrating that plogosertib, a PLK1 inhibitor, is active in...
Tonix Pharmaceuticals (NASDAQ: TNXP) has announced the publication of a paper in the peer-reviewed journal Cancer Cell, presenting data demonstrating that treatment with murine TNX-1700 (mTNX-1700) increased survival...
BriaCell Therapeutics (NASDAQ: BCTX, BCTXW, BCTXZ; TSX: BCT) has announced the addition of two major cancer centers to its ongoing pivotal Phase 3 clinical study of Bria-IMT plus immune checkpoint inhibitor versus...
Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that the first patient has been dosed in its Phase 1/2a clinical trial of its proprietary MEAI-based oral drug candidate, CMND-100, for the treatment of alcohol...
Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that Medical City Dallas Hospital—an award-winning, 899-bed acute care hospital in the Dallas-Fort Worth area—has adopted the company’s current...
Artelo Biosciences (NASDAQ: ARTL) has announced positive results from its first-in-human study evaluating its novel non-opioid candidate, ART26.12, for the treatment of persistent pain. ART26.12 is the first orally...
KalVista Pharmaceuticals (NASDAQ: KALV) has announced that it has entered into a licensing agreement with closely held Pendopharm to manage the regulatory approval process and commercialization of sebetralstat, an...
Theravance Biopharma (NASDAQ: TBPH) has announced that China’s National Medical Products Administration (NMPA) has granted regulatory approval for YUPELRI, the company’s revefenacin inhalation solution for the treatment...
QT Imaging (QTCQB: QTIH) has announced the release ofits latest image reconstruction software update, version 4.4.0, significantly reducing QTscan image processing time and improving user throughput and overall...
Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has added Tel Aviv Sourasky Medical Center (TASMC) to the list of clinical sites for its ongoing Phase 1/2a trial evaluating CMND-100—a proprietary MEAI...
Immunic (NASDAQ: IMUX) has announced new, positive long-term open-label extension (OLE) data from its Phase 2 EMPhASIS trial of lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus...
ArriVent BioPharma (NASDAQ: AVBP) announced encouraging additional follow-up proof-of-concept data from its global Phase 1b FURTHER trial of first-line firmonertinib monotherapy in patients with non-small cell lung...
Compass Pathways (NASDAQ: CMPS) announced that it has achieved the primary endpoint in the first of two ongoing Phase 3 trials evaluating COMP005 psilocybin for treatment-resistant depression (TRD). The ongoing Phase 3...
Firefly Neuroscience (NASDAQ: AIFF) has announced a significant advancement in Alzheimer’s disease research: the company has identified a novel, objective method for measuring and distinguishing between subjective...